ANI Pharmaceuticals, Inc. $ANIP Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 39.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,508 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,975 shares during the quarter. Intech Investment Management LLC owned 0.17% of ANI Pharmaceuticals worth $3,040,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its holdings in shares of ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $28,000. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Federated Hermes Inc. acquired a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $93,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of ANI Pharmaceuticals by 30.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 253 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In related news, SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total value of $220,374.00. Following the completion of the sale, the senior vice president owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This represents a 20.65% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 88,950 shares of company stock valued at $6,900,618. 8.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $74.65 on Wednesday. ANI Pharmaceuticals, Inc. has a one year low of $59.61 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock has a market cap of $1.70 billion, a PE ratio of 18.90 and a beta of 0.44. The stock has a 50 day moving average price of $78.77 and a 200 day moving average price of $79.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter last year, the firm earned $1.70 earnings per share. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.96 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the subject of a number of research analyst reports. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.